Syndax Pharmaceuticals Inc SNDX

Latest FY: 2025 Healthcare Biotechnology
Market Price $19.85
Market Cap $1.69B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑627.8% YoY
$172.35M
Full year reported
Net Income ↑10.5% YoY
-$285.42M
Net Margin: -165.6%
Free Cash Flow ↓-17.6% YoY
-$323.17M
FCF Yield: -19.12%
EPS (Diluted) ↑11.6% YoY
$-3.29
Basic: $-3.29
Return on Equity Efficiency
-441.6%
ROA: -2,114.9%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (SNDX)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2019: Revenue YoY (+0.0%) is identical to Gross Profit YoY (+0.0%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
  • FY 2020: Revenue YoY (+0.0%) is identical to Gross Profit YoY (+0.0%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $1.2M $0.3M $-44.5M $-3.22 $-35.2M $-35.4M
FY 2017 $2.1M +72.8% $0.7M $-60.8M -36.7% $-2.90 +9.9% $-47.4M $-47.5M -34.0%
FY 2018 $1.5M -28.0% $1.5M $-74.0M -21.6% $-2.92 -0.7% $-68.5M $-68.7M -44.8%
FY 2019 $1.5M 0.0% $1.5M $-56.0M +24.2% $-1.84 +37.0% $-50.6M $-50.8M +26.1%
FY 2020 $1.5M 0.0% $1.5M $-73.2M -30.5% $-1.87 -1.6% $-71.3M $-71.3M -40.3%
FY 2021 $139.7M +9,109.6% $137.8M $24.9M +134.1% $0.46 +124.6% $29.1M $29.0M +140.7%
FY 2022 -100.0% $-149.3M -699.1% $-2.46 -634.8% $-133.7M $-133.7M -560.9%
FY 2023 $-209.4M -40.2% $-2.98 -21.1% $-160.6M $-160.6M -20.1%
FY 2024 $23.7M $18.8M $-318.8M -52.3% $-3.72 -24.8% $-274.9M $-274.9M -71.2%
FY 2025 $172.4M +627.8% $172.3M $-285.4M +10.5% $-3.29 +11.6% $-323.0M $-323.2M -17.6%
$

Valuation

Market Price $19.85
Market Cap $1.69B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio 27.22
FCF Yield -19.12%
Dividend Yield N/A
Shares Outstanding 88,610,000
%

Profitability & Margins

Gross Margin 100.00%
Operating Margin -158.45%
Net Margin -165.60%
Return on Equity (ROE) -441.62%
Return on Assets (ROA) -2,114.86%
Asset Turnover 12.77x
Revenue 3-Yr CAGR N/A
🛡️

Financial Health & Liquidity

Current Ratio 0.11
Cash Ratio 1.12
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $134.93M
Total Debt N/A
Book Value / Share $0.73
💧

Cash Flow Efficiency

Operating Cash Flow -$322.98M
Capital Expenditures (CapEx) $187.00K
Free Cash Flow -$323.17M
OCF / Revenue -187.40%
FCF / Revenue -187.50%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-3.29
EPS (Basic) $-3.29
Dividends / Share N/A
Book Value / Share $0.73
EPS YoY Growth 11.56%
🏛️

Balance Sheet (FY 2025)

Total Assets $13.50M
Total Liabilities $120.12M
Stockholders' Equity $64.63M
Current Assets $13.50M
Current Liabilities $120.12M